Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.
复制标题
DOI：
10.1007/s10147-021-01881-4
复制
发表时间：
2021-08
影响因子：
3.3
通讯作者：
Japanese Society for Cancer of the Colon, Rectum
中科院分区：
文献类型：
--
作者：
Tomita N;Ishida H;Tanakaya K;Yamaguchi T;Kumamoto K;Tanaka T;Hinoi T;Miyakura Y;Hasegawa H;Takayama T;Ishikawa H;Nakajima T;Chino A;Shimodaira H;Hirasawa A;Nakayama Y;Sekine S;Tamura K;Akagi K;Kawasaki Y;Kobayashi H;Arai M;Itabashi M;Hashiguchi Y;Sugihara K;Japanese Society for Cancer of the Colon, Rectum
遗传性结直肠癌（HCRC）占所有结直肠癌病例的< 5%。HCRC病例中常见的一些独特特征包括发病年龄早，同步/异时癌症发生以及其他器官中的多种癌症。这些特点需要不同的管理方法，包括诊断，治疗或监测，从散发性结直肠癌的管理。有两种代表性的HCRC，命名为家族性腺瘤性息肉病和Lynch综合征。除了这两个HCRC综合征，相关疾病也有报道。世界各地已经出版了几份关于遗传性疾病的指南。在日本，HCRC的第一个指南由日本结肠直肠癌学会（JSCCR）编写，于2012年发布，并于2016年修订。该指南的修订版立即被翻译成英文并于2017年出版。从那时起，已经发现了与HCRC相关的一些新发现和新疾病概念。在日常临床实践中，目前诊断的HCRC率相对较低;然而，随着癌症多基因组检测或全基因组检测等的进步，预计在癌症基因组医学时代这一比率将增加。在这种情况下，JSCCR HCRC指南委员会成员在仔细审查文献检索中检索到的证据的基础上，并考虑到日本的医疗健康保险制度和实际临床实践环境，通过协商一致编制了JSCCR HCRC指南2020。在此，我们为HCRC提供了JSCCR指南2020的英文版本。
Hereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics necessitate different management approaches, including diagnosis, treatment or surveillance, from sporadic colorectal cancer management. There are two representative HCRC, named familial adenomatous polyposis and Lynch syndrome. Other than these two HCRC syndromes, related disorders have also been reported. Several guidelines for hereditary disorders have already been published worldwide. In Japan, the first guideline for HCRC was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016. This revised version of the guideline was immediately translated into English and published in 2017. Since then, several new findings and novel disease concepts related to HCRC have been discovered. The currently diagnosed HCRC rate in daily clinical practice is relatively low; however, this is predicted to increase in the era of cancer genomic medicine, with the advancement of cancer multi-gene panel testing or whole genome testing, among others. Under these circumstances, the JSCCR guidelines 2020 for HCRC were prepared by consensus among members of the JSCCR HCRC Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR guidelines 2020 for HCRC.
登录
查看更多内容
影响因子：
7.2
作者：
通讯作者：
--
影响因子：
9.6
作者：
Aziz, O;Athanasiou, T;Tekkis, PP
通讯作者：
Tekkis, PP
影响因子：
2.2
作者：
Barrow, Emma;Hill, James;Evans, D. Gareth
通讯作者：
Evans, D. Gareth
影响因子：
9.8
作者：
BENNETT, RL;STEINHAUS, KA;HAMANISHI, J
通讯作者：
HAMANISHI, J
影响因子：
1.9
作者：
Bennett, Robin L;French, Kathryn Steinhaus;Doyle, Debra Lochner
通讯作者：
Doyle, Debra Lochner